Tanezumab for the Treatment of Pain from Osteoarthri

New England Journal of Medicine
363, 1521-1531
DOI: 10.1056/nejmoa0901510

Citation Report

#	Article	IF	Citations
1	Inhibitor of nerve growth factor relieves OA pain. Nature Reviews Rheumatology, 2010, 6, 676-676.	3.5	0
2	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2010, 45, 953-955.	0.4	0
4	Nerve Growth Factor and Pain. New England Journal of Medicine, 2010, 363, 1572-1573.	13.9	50
5	Update on peripheral mechanisms of pain: beyond prostaglandins and cytokines. Arthritis Research and Therapy, 2011, 13, 210.	1.6	118
6	New takes on treatment and prevention. Nature Reviews Rheumatology, 2011, 7, 75-76.	3.5	9
7	What makes osteoarthritis painful? The evidence for local and central pain processing. Rheumatology, 2011, 50, 2157-2165.	0.9	165
8	Emerging drugs for osteoarthritis. Expert Opinion on Emerging Drugs, 2011, 16, 479-491.	1.0	82
9	The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A. Neuroscience, 2011, 178, 196-207.	1.1	162
10	Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation. Neuroscience, 2011, 193, 452-465.	1.1	16
11	Douleur et immunitÃ©. Revue Du Rhumatisme (Edition Francaise), 2011, 78, 503-511.	0.0	0
12	Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated With Interstitial Cystitis. Journal of Urology, 2011, 185, 1716-1721.	0.2	148
13	Selectivity of Cell Signaling in the Neuronal Response Based on NGF Mutations and Peptidomimetics in the Treatment of Alzheimers Disease. , 2011, , .		0
14	Antagonism of Nerve Growth Factor-TrkA Signaling and the Relief of Pain. Anesthesiology, 2011, 115, 189-204.	1.3	285
15	Association of osteonecrosis and peripheral neuropathy in HIV-1-infected patients. Aids, 2011, 25, 2305-2306.	1.0	1
16	The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. Aids, 2011, 25, 2308-2310.	1.0	23
17	Recent Clinical Evidence for the Treatment of Osteoarthritis: What we have Learned. Reviews on Recent Clinical Trials, 2011, 6, 114-126.	0.4	10
18	Targeted treatment of pruritus: a look into the future. British Journal of Dermatology, 2011, 165, 5-17.	1.4	86
19	Perineural invasion and associated pain in pancreatic cancer. Nature Reviews Cancer, 2011, 11, 695-707.	12.8	348

#	Article	IF	Citations
20	Fate of novel painkiller mAbs hangs in balance. Nature Biotechnology, 2011, 29, 173-174.	9.4	26
21	Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis and Cartilage, 2011, 19, 639-646.	0.6	111
22	Osteoarthritis year 2010 in review: pharmacological therapies. Osteoarthritis and Cartilage, 2011, 19, 361-365.	0.6	43
23	Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis and Cartilage, 2011, 19, 1405-1412.	0.6	74
24	New Concepts in Pain Research and Pain Management of the Rheumatic Diseases. Seminars in Arthritis and Rheumatism, 2011, 41, 319-334.	1.6	48
25	Mitochondrial dependence of nerve growth factor-induced mechanical hyperalgesia. Pain, 2011, 152, 1832-1837.	2.0	17
26	Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain, 2011, 152, 2248-2258.	2.0	214
27	Nerve growth factor selectively decreases activity-dependent conduction slowing in mechano-insensitive C-nociceptors. Pain, 2011, 152, 2138-2146.	2.0	29
28	Blocking the effects of NGF as a route to safe and effective pain relief â€“ fact or fancy?. Pain, 2011, 152, 2200-2201.	2.0	10
29	Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain, 2011, 152, 2564-2574.	2.0	156
30	A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regulatory Toxicology and Pharmacology, 2011, 59, 334-342.	1.3	25
31	A Variant in MCF2L Is Associated with Osteoarthritis. American Journal of Human Genetics, 2011, 89, 446-450.	2.6	115
32	Ion channels in inflammation. Pflugers Archiv European Journal of Physiology, 2011, 461, 401-421.	1.3	90
33	The effects of radiofrequency hyperthermia on pain and function in patients with knee osteoarthritis: a preliminary report. Journal of Orthopaedic Science, 2011, 16, 376-381.	0.5	23
34	Genetic variability of pain perception and treatmentâ€"clinical pharmacological implications. European Journal of Clinical Pharmacology, 2011, 67, 541-551.	0.8	24
35	Non-surgical treatment of osteoarthritis-related pain in the elderly. Current Reviews in Musculoskeletal Medicine, 2011, 4, 113-122.	1.3	26
36	Growth Factors and Neuropathic Pain. Current Pain and Headache Reports, 2011, 15, 185-192.	1.3	44
37	A Study to Investigate Tanezumab in Patients with Interstitial Cystitis/Painful Bladder Syndrome. Current Urology Reports, 2011, 12, 245-246.	1.0	10

#	Article	IF	Citations
38	Pharmacological modulation of central nociception in the management of chronic musculoskeletal pain. Pain Management, 2011, 1, 549-556.	0.7	2
40	Interview: Key questions in pain research: clinical observations informing research and vice versa. Pain Management, 2011, 1, 123-125.	0.7	0
41	Biologics: the next-generation therapeutics for analgesia?. Expert Review of Neurotherapeutics, 2011, 11, 1653-1658.	1.4	5
42	New molecules for the treatment of pain. Current Opinion in Supportive and Palliative Care, 2011, 5, 111-115.	0.5	20
43	Treating the Pain of Osteoarthritis â€" Where Do We Go from Here?. Journal of Rheumatology, 2011, 38, 1535-1537.	1.0	7
44	Perioperative Nerve Blockade: Clues from the Bench. Anesthesiology Research and Practice, 2011, 2011, 1-12.	0.2	9
45	A Virus-Like Particle-Based Anti-Nerve Growth Factor Vaccine Reduces Inflammatory Hyperalgesia: Potential Long-Term Therapy for Chronic Pain. Journal of Immunology, 2011, 186, 1769-1780.	0.4	29
46	Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. Aids, 2011, 25, 2306-2308.	1.0	5
47	The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial. Annals of the Rheumatic Diseases, 2011, 70, 1191-1196.	0.5	32
48	Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20455-20460.	3.3	100
49	New targets, new drugs for metastatic bone pain: a new philosophy. Expert Opinion on Emerging Drugs, 2011, 16, 403-405.	1.0	17
50	The nuts and bolts of pills and potions: the functions of a drug safety working group. Australian Health Review, 2011, 35, 395.	0.5	0
51	Nerve Growth Factor in Cancer Cell Death and Survival. Cancers, 2011, 3, 510-530.	1.7	92
52	Treatment Options for Osteoarthritis: Considerations for Older Adults. Hospital Practice (1995), 2011, 39, 62-73.	0.5	14
53	Pain and Palliative Care Pharmacotherapy Literature Summaries and Analyses. Journal of Pain and Palliative Care Pharmacotherapy, 2011, 25, 178-183.	0.5	1
54	Osteoarthritis: a holistic approach. Clinical Medicine, 2012, 12, 153-155.	0.8	5
55	Targeted drug development for arthritis. Future Medicinal Chemistry, 2012, 4, 701-703.	1.1	11
56	Analgesics for Cancer Pain. , 2012, , .		0

#	Article	IF	Citations
57	Ultrasound-guided platelet-rich plasma injections for the treatment of osteoarthritis of the hip. Rheumatology, 2012, 51, 144-150.	0.9	168
58	Sensory innervation and inflammatory cytokines in hypertrophic synovia associated with pain transmission in osteoarthritis of the hip: a case-control study. Rheumatology, 2012, 51, 1790-1795.	0.9	28
61	The Perception and Endogenous Modulation of Pain. Scientifica, 2012, 2012, 1-25.	0.6	53
62	Medical Food and Food Supplements: Not Always as Safe as Generally Assumed. Annals of Internal Medicine, 2012, 156, 894.	2.0	8
63	Non-specific low back pain. Lancet, The, 2012, 379, 482-491.	6.3	1,297
64	Meteorin reverses hypersensitivity in rat models of neuropathic pain. Experimental Neurology, 2012, 237, 260-266.	2.0	13
65	Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochemistry International, 2012, 61, 1266-1275.	1.9	58
66	Preliminary Assessment of Safety and Efficacy in Proof-of-Concept, Randomized Clinical Trial of Tanezumab for Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Urology, 2012, 80, 1105-1110.	0.5	44
67	Deconstructing the Neuropathic Pain Phenotype to Reveal Neural Mechanisms. Neuron, 2012, 73, 638-652.	3.8	689
68	Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial. Journal of Pain, 2012, 13, 790-798.	0.7	166
69	Future therapeutics for osteoarthritis. Bone, 2012, 51, 297-311.	1.4	93
70	Osteochondral alterations in osteoarthritis. Bone, 2012, 51, 204-211.	1.4	256
71	Genetic factors in OA pathogenesis. Bone, 2012, 51, 258-264.	1.4	71
72	Biologics: the next generation of analgesic drugs?. Drug Discovery Today, 2012, 17, 875-879.	3.2	16
73	Skin innervation at different depths correlates with small fibre function but not with pain in neuropathic pain patients. European Journal of Pain, 2012, 16, 1414-1425.	1.4	43
74	Keratinocyte expression of inflammatory mediators plays a crucial role in substance P-induced acute and chronic pain. Journal of Neuroinflammation, 2012, 9, 181.	3.1	55
75	Joint pathology and platelet-rich plasma therapies. Expert Opinion on Biological Therapy, 2012, 12, 7-22.	1.4	91
76	Unraveling the mystery of pain in chronic pancreatitis. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 140-151.	8.2	96

#	Article	IF	Citations
77	Neurotrophins as regulators of urinary bladder function. Nature Reviews Urology, 2012, 9, 628-637.	1.9	78
78	Pain mediators and wound healingâ€"Establishing the connection. Burns, 2012, 38, 951-959.	1.1	47
79	Control of Arthritis Pain with Antiâ€"Nerve-Growth Factor: Risk and Benefit. Current Rheumatology Reports, 2012, 14, 583-588.	2.1	36
80	Mechanisms of Chronic Pain in Osteoarthritis. Current Rheumatology Reports, 2012, 14, 549-556.	2.1	180
82	Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice. Arthritis Research and Therapy, 2012, 14, R101.	1.6	87
83	Single Cycle Structure-Based Humanization of an Anti-Nerve Growth Factor Therapeutic Antibody. PLoS ONE, 2012, 7, e32212.	1.1	8
84	Gait Analysis in Rats with Single Joint Inflammation: Influence of Experimental Factors. PLoS ONE, 2012, 7, e46129.	1.1	27
85	NGF – the TrkA to successful pain treatment. Journal of Pain Research, 2012, 5, 279.	0.8	65
87	Osteoarthritis genetic factors animal models mechanisms and therapies. Frontiers in Bioscience - Elite, 2012, E4, 74-100.	0.9	57
88	Management of osteoarthritis of the knee. BMJ, The, 2012, 345, e4934-e4934.	3.0	154
89	Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis and Rheumatism, 2012, 64, 2223-2232.	6.7	127
90	Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis. Nature Reviews Rheumatology, 2012, 8, 390-398.	3.5	418
91	Pain and immunity. Joint Bone Spine, 2012, 79, 228-236.	0.8	29
92	Chronic pain: genes, plasticity, and phenotypes. Lancet Neurology, The, 2012, 11, 19-21.	4.9	37
93	Evidence-Based Knee Injections for the Management of Arthritis. Pain Medicine, 2012, 13, 740-753.	0.9	134
94	Weight change in osteoarthritis. Osteoarthritis and Cartilage, 2012, 20, 268-270.	0.6	4
95	Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. Orphanet Journal of Rare Diseases, 2012, 7, S3.	1.2	98
96	Mechanisms of Pain in Osteoarthritis. HSS Journal, 2012, 8, 26-28.	0.7	38

#	Article	IF	Citations
97	Nerve growth factor: an update on the science and therapy. Osteoarthritis and Cartilage, 2013, 21, 1223-1228.	0.6	72
98	Genomics of pain in osteoarthritis. Osteoarthritis and Cartilage, 2013, 21, 1374-1382.	0.6	32
99	Identification of novel pyrazoloquinazolinecarboxilate analogues to inhibit nerve growth factor in vitro. European Journal of Pharmacology, 2013, 708, 30-37.	1.7	17
100	Nociceptive Physiology. , 2013, , 235-252.		3
101	A commentary on modelling osteoarthritis pain in small animals. Osteoarthritis and Cartilage, 2013, 21, 1316-1326.	0.6	121
102	New horizons in osteoarthritis. Age and Ageing, 2013, 42, 272-278.	0.7	49
103	Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain, 2013, 154, 1009-1021.	2.0	131
104	Chemokine Expression in Peripheral Tissues from the Monosodium Lodoacetate Model of Chronic Joint Pain. Molecular Pain, 2013, 9, 1744-8069-9-57.	1.0	31
105	A fully caninised anti-NGF monoclonal antibody for pain relief in dogs. BMC Veterinary Research, 2013, 9, 226.	0.7	32
106	The Future of Osteoarthritis Therapeutics: Emerging Biological Therapy. Current Rheumatology Reports, 2013, 15, 385.	2.1	63
107	Towards a mechanism-based approach to pain management in osteoarthritis. Nature Reviews Rheumatology, 2013, 9, 654-664.	3.5	242
108	Targeting novel peripheral mediators for the treatment of chronic pain. British Journal of Anaesthesia, 2013, 111, 46-51.	1.5	40
109	Genes and epigenetic processes as prospective pain targets. Genome Medicine, 2013, 5, 12.	3.6	57
110	Characterization of nerve growth factorâ€induced mechanical and thermal hypersensitivity in rats. European Journal of Pain, 2013, 17, 469-479.	1.4	58
111	A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain, 2013, 154, 1603-1612.	2.0	108
112	Sciatic nerve regeneration is not inhibited by anti-NGF antibody treatment in the adult rat. Neuroscience, 2013, 241, 157-169.	1.1	10
113	Chemokines as peripheral pain mediators. Neuroscience Letters, 2013, 557, 1-8.	1.0	37
114	Wound-healing growth factor, basic FGF, induces Erk1/2-dependent mechanical hyperalgesia. Pain, 2013, 154, 2216-2226.	2.0	41

#	Article	IF	Citations
115	Genes, molecules and patientsâ€"Emerging topics to guide clinical pain research. European Journal of Pharmacology, 2013, 716, 188-202.	1.7	11
116	Nerve growth factor induces sensitization of nociceptors without evidence for increased intraepidermal nerve fiber density. Pain, 2013, 154, 2500-2511.	2.0	56
117	Nerve growth factorâ€mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. Journal of Neurochemistry, 2013, 124, 276-289.	2.1	116
118	Clinical targeting of the TNF and TNFR superfamilies. Nature Reviews Drug Discovery, 2013, 12, 147-168.	21.5	364
119	Biologic agents in osteoarthritis: hopes and disappointments. Nature Reviews Rheumatology, 2013, 9, 400-410.	3.5	186
120	Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. Pain, 2013, 154, 1910-1919.	2.0	88
121	Axonal voltage-gated ion channels as pharmacological targets for pain. European Journal of Pharmacology, 2013, 708, 105-112.	1.7	25
122	New and Developing Drugs for the Treatment of Neuropathic Pain in Diabetes. Current Diabetes Reports, 2013, 13, 500-508.	1.7	19
123	Sequential Protein and Peptide Immunoaffinity Capture for Mass Spectrometry-Based Quantification of Total Human Î²-Nerve Growth Factor. Analytical Chemistry, 2013, 85, 1719-1726.	3.2	117
124	Inflammation meets sensitizationâ€"an explanation for spontaneous nociceptor activity?. Pain, 2013, 154, 2707-2714.	2.0	17
125	Advances in osteoarthritis genetics: TableÂ1. Journal of Medical Genetics, 2013, 50, 715-724.	1.5	51
127	Neuropathic Features of Joint Pain: A Communityâ€Based Study. Arthritis and Rheumatism, 2013, 65, 1942-1949.	6.7	66
128	Tanezumab Reduces Osteoarthritic Hip Pain: Results of a Randomized, Doubleâ€Blind, Placeboâ€Controlled Phase III Trial. Arthritis and Rheumatism, 2013, 65, 1795-1803.	6.7	110
129	Changes in Pressure Pain Threshold in Patients With Chronic Nonspecific Low Back Pain. Spine, 2013, 38, 2098-2107.	1.0	75
130	New treatments for osteoarthritis. Current Opinion in Rheumatology, 2013, 25, 310-316.	2.0	49
131	Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus, 2013, 3, 20120071.	1.5	20
132	Immunosympathectomy as the first phenotypic knockout with antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4877-4885.	3.3	4
133	Relationship Between Persistent Pain and 5â€Year Mortality: A Populationâ€Based Prospective Cohort Study. Journal of the American Geriatrics Society, 2013, 61, 2135-2141.	1.3	24

#	Article	IF	Citations
134	Osteoarthritis â€“ Genetic Studies of Monogenic and Complex Forms. , 2013, , 275-293.		3
135	Local nociceptor sensitization with <scp>NGF</scp>: Mechanical or heat hyperalgesia Ã¡ la carte?. European Journal of Pain, 2013, 17, 467-468.	1.4	0
136	The Effect of Anti-NGF Receptor (p75 Neurotrophin Receptor) Antibodies on Nociceptive Behavior and Activation of Spinal Microglia in the Rat Brachial Plexus Avulsion Model. Spine, 2013, 38, E332-E338.	1.0	17
138	Getting tough on pain. EMBO Reports, 2013, 14, 236-238.	2.0	1
139	Pharmacological pain management in chronic pancreatitis. World Journal of Gastroenterology, 2013, 19, 7292.	1.4	43
141	Peripheral and central sensitization. , 0, , 51-64.		1
142	Postamputation pain: epidemiology, mechanisms, and treatment. Journal of Pain Research, 2013, 6, 121.	0.8	199
143	Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study. Journal of Pain Research, 2014, 7, 523.	0.8	13
144	Systems Pharmacology of the NGF Signaling Through p75 and TrkA Receptors. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-8.	1.3	14
145	Augmented pain behavioural responses to intra-articular injection of nerve growth factor in two animal models of osteoarthritis. Annals of the Rheumatic Diseases, 2014, 73, 1710-1718.	0.5	81
146	Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial. Neurology, 2014, 83, 628-637.	1.5	35
147	Nerve growth factor promotes expression of novel genes in intervertebral disc cells that regulate tissue degradation. Journal of Neurosurgery: Spine, 2014, 21, 653-661.	0.9	19
148	Future directions for the management of pain in osteoarthritis. International Journal of Clinical Rheumatology, 2014, 9, 197-216.	0.3	33
149	Morphologic, Stereologic, and Morphometric Evaluation of the Nervous System in Young Cynomolgus Monkeys (Macaca fascicularis) Following Maternal Administration of Tanezumab, a Monoclonal Antibody to Nerve Growth Factor. Toxicological Sciences, 2014, 142, 463-476.	1.4	21
150	Neurotrophin and endocannabinoid interactions in the neurobiology of pain. European Journal of Neuroscience, 2014, 39, 331-333.	1.2	1
151	High hopes for cannabinoid agonists in the treatment of rheumatic diseases. BMC Musculoskeletal Disorders, 2014, 15, 410.	0.8	2
152	The effect on knee-joint load of instruction in analgesic use compared with neuromuscular exercise in patients with knee osteoarthritis: study protocol for a randomized, single-blind, controlled trial (the EXERPHARMA trial). Trials, 2014, 15, 444.	0.7	22
153	Structural Associations of Symptomatic Knee Osteoarthritis. Arthritis and Rheumatology, 2014, 66, 3018-3027.	2.9	108

#	Article	IF	Citations
154	Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized Fab-antigen complexes. MAbs, 2014, 6, 1059-1068.	2.6	7
155	Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. Arthritis Research and Therapy, 2014, 16, R16.	1.6	96
156	Increase of nerve growth factor levels in the human herniated intervertebral disc: can annular rupture trigger discogenic back pain?. Arthritis Research and Therapy, 2014, 16, R159.	1.6	33
157	Genetics of disc-related disorders: current findings and lessons from other complex diseases. European Spine Journal, 2014, 23, 354-363.	1.0	23
158	The neurobiology of skeletal pain. European Journal of Neuroscience, 2014, 39, 508-519.	1.2	146
159	Modulation of Neurotrophin Signaling by Monoclonal Antibodies. Handbook of Experimental Pharmacology, 2014, 220, 497-512.	0.9	9
161	Nerve Growth Factor and Nociception: From Experimental Embryology to New Analgesic Therapy. Handbook of Experimental Pharmacology, 2014, 220, 251-282.	0.9	63
162	Behavioral Pharmacology of Pain. Current Topics in Behavioral Neurosciences, 2014, 20, 33-56.	0.8	4
163	Emerging drugs for neuropathic pain. Expert Opinion on Emerging Drugs, 2014, 19, 329-341.	1.0	62
164	Targeting Nerve Growth Factor (NGF) for Pain Management: What Does the Future Hold for NGF Antagonists?. Drugs, 2014, 74, 619-626.	4.9	101
165	Predictors of Short-Term Outcome to Exercise and Manual Therapy for People With Hip Osteoarthritis. Physical Therapy, 2014, 94, 31-39.	1.1	23
166	Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Annals of the Rheumatic Diseases, 2014, 73, 1665-1672.	0.5	75
167	A Pain Research Agenda for the 21st Century. Journal of Pain, 2014, 15, 1203-1214.	0.7	145
168	Proâ€neurotrophins, sortilin, and nociception. European Journal of Neuroscience, 2014, 39, 363-374.	1.2	44
169	Nociceptive phenotype of dorsal root ganglia neurons innervating the subchondral bone in rat knee joints. European Journal of Pain, 2014, 18, 174-181.	1.4	31
170	Neurotrophins in bladder function: What do we know and where do we go from here?. Neurourology and Urodynamics, 2014, 33, 39-45.	0.8	58
171	Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of Osteoarthritis: 2 Randomized Controlled Trials versus Naproxen. Journal of Rheumatology, 2014, 41, 2249-2259.	1.0	72
172	In VivoRegulation of NGF-Mediated Functions by Nedd4-2 Ubiquitination of TrkA. Journal of Neuroscience, 2014, 34, 6098-6106.	1.7	38

#	Article	IF	Citations
173	Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain. Pain, 2014, 155, 1793-1801.	2.0	50
174	Electronic health databases for epidemiological research on joint replacements: considerations when making cross-national comparisons. Annals of Epidemiology, 2014, 24, 660-665.	0.9	17
175	Tropomyosin receptor kinase inhibitors: a patent update 2009 â€“ 2013. Expert Opinion on Therapeutic Patents, 2014, 24, 731-744.	2.4	15
176	Update on biological therapies for knee injuries: osteoarthritis. Current Reviews in Musculoskeletal Medicine, 2014, 7, 263-269.	1.3	14
177	Peripheral changes in endometriosis-associated pain. Human Reproduction Update, 2014, 20, 717-736.	5.2	135
178	Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. Journal of the Neurological Sciences, 2014, 345, 139-147.	0.3	34
179	The role of imaging modalities in the diagnosis, differential diagnosis and clinical assessment of peripheral joint osteoarthritis. Osteoarthritis and Cartilage, 2014, 22, 1692-1702.	0.6	40
180	Importance of subchondral bone in the pathogenesis and management of osteoarthritis from bench to bed. Journal of Orthopaedic Translation, 2014, 2, 16-25.	1.9	27
181	NGF-induced mechanical sensitization of the masseter muscle is mediated through peripheral NMDA receptors. Neuroscience, 2014, 269, 232-244.	1.1	56
182	TNF-Î±/TNFR1 Signaling Is Required for the Development and Function of Primary Nociceptors. Neuron, 2014, 82, 587-602.	3.8	75
183	Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain, 2014, 155, 1245-1252.	2.0	85
184	Canine Brief Pain Inventory scores for dogs with osteoarthritis before and after administration of a monoclonal antibody against nerve growth factor. American Journal of Veterinary Research, 2014, 75, 532-535.	0.3	32
185	Maximizing Diversity from a Kinase Screen: Identification of Novel and Selective pan-Trk Inhibitors for Chronic Pain. Journal of Medicinal Chemistry, 2014, 57, 5800-5816.	2.9	52
186	Boneâ€“cartilage interface crosstalk in osteoarthritis: potential pathways and future therapeutic strategies. Osteoarthritis and Cartilage, 2014, 22, 1077-1089.	0.6	220
187	Neuropathic pain in osteoarthritis: A review of pathophysiological mechanisms and implications for treatment. Seminars in Arthritis and Rheumatism, 2014, 44, 145-154.	1.6	157
188	Efficacy of Antiâ€“Nerve Growth Factor Therapy for Discogenic Neck Pain in Rats. Spine, 2014, 39, E757-E762.	1.0	13
189	OsteoRheumatology: a new discipline?. RMD Open, 2015, 1, e000083.	1.8	9
190	Cartilage stem/progenitor cells are activated in osteoarthritis via interleukin-1Î²/nerve growth factor signaling. Arthritis Research and Therapy, 2015, 17, 327.	1.6	40

#	Article	IF	Citations
191	Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects. Arthritis Research and Therapy, 2015, 17, 282.	1.6	20
192	Efficacy and safety of tanezumab in the treatment of pain from bone metastases. Pain, 2015, 156, 1703-1713.	2.0	64
193	Neurotrophins and Neuropathic Pain: Role in Pathobiology. Molecules, 2015, 20, 10657-10688.	1.7	145
194	Efficacy of Direct Injection of Etanercept into Knee Joints for Pain in Moderate and Severe Knee Osteoarthritis. Yonsei Medical Journal, 2015, 56, 1379.	0.9	47
195	The Future of Pain Pharmacotherapy. , 2015, , 197-207.		0
196	Mechanisms and Mediators That Drive Arthritis Pain. Current Osteoporosis Reports, 2015, 13, 216-224.	1.5	50
197	A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain. BMC Veterinary Research, 2015, 11, 101.	0.7	72
198	Implementation of maximin efficient designs in doseâ€finding studies. Pharmaceutical Statistics, 2015, 14, 63-73.	0.7	5
199	New Mendelian Disorders of Painlessness. Trends in Neurosciences, 2015, 38, 712-724.	4.2	32
200	TGF-Î² is a potent inducer of Nerve Growth Factor in articular cartilage via the ALK5-Smad2/3 pathway. Potential role in OA related pain?. Osteoarthritis and Cartilage, 2015, 23, 478-486.	0.6	66
201	Exploring the Role of Tanezumab as a Novel Treatment for the Relief of Neuropathic Pain. Pain Medicine, 2015, 16, 1163-1176.	0.9	58
202	Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis. Osteoarthritis and Cartilage, 2015, 23, 925-932.	0.6	43
203	Pharmacological Treatment of Pain: Future Trends and Novel Insights. Clinical Pharmacology and Therapeutics, 2015, 97, 104-108.	2.3	2
204	Crosstalk between the nociceptive and immune systems in host defence and disease. Nature Reviews Neuroscience, 2015, 16, 389-402.	4.9	148
205	The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain. Current Osteoporosis Reports, 2015, 13, 318-326.	1.5	31
207	Using gait analysis to assess weight bearing in rats with Freund×3s complete adjuvant-induced monoarthritis to improve predictivity: Interfering with the cyclooxygenase and nerve growth factor pathways. European Journal of Pharmacology, 2015, 756, 75-84.	1.7	11
208	Emerging drugs for the treatment of knee osteoarthritis. Expert Opinion on Emerging Drugs, 2015, 20, 361-378.	1.0	40
209	Anti-arthritic agents: Progress and potential. Bioorganic and Medicinal Chemistry, 2015, 23, 3059-3080.	1.4	67

#	Article	IF	Citations
211	Emerging Concepts of Pain Therapy Based on Neuronal Mechanisms. Handbook of Experimental Pharmacology, 2015, 227, 1-14.	0.9	13
212	Itch and Pain Differences and Commonalities. Handbook of Experimental Pharmacology, 2015, 227, 285-301.	0.9	31
214	Pharmacology of Itch. Handbook of Experimental Pharmacology, 2015, , .	0.9	3
215	Calcitonin geneâ€related peptide in the joint: contributions to pain and inflammation. British Journal of Clinical Pharmacology, 2015, 80, 965-978.	1.1	97
216	Orthopedic surgery and bone fracture pain are both significantly attenuated by sustained blockade of nerve growth factor. Pain, 2015, 156, 157-165.	2.0	45
217	Botulinum Toxin Treatment of Pain Disorders. , 2015, , .		10
218	An Analysis of US Food and Drug Administration Clinical Hold Orders for Drugs and Biologics: A Prospective Study Between 2008 and 2014. Pharmaceutical Medicine, 2015, 29, 203-209.	1.0	4
219	Comparison of nerve growth factorâ€“induced sensitization pattern in lumbar and tibial muscle and fascia. Muscle and Nerve, 2015, 52, 265-272.	1.0	22
220	Safety Profile of Current OA Therapies: Evidence from Clinical Trials. , 2015, , 211-234.		1
221	Investigational drugs for the treatment of osteoarthritis. Expert Opinion on Investigational Drugs, 2015, 24, 1539-1556.	1.9	47
222	Regenerative Medicine Approaches for Treatment of Osteoarthritis. , 2015, , 235-255.		0
223	The Effects of Generally Administered Antiâ€“Nerve Growth Factor Receptor (p75NTR) Antibody on Pain-Related Behavior, Dorsal Root Ganglia, and Spinal Glia Activation in a Rat Model of Brachial Plexus Avulsion. Journal of Hand Surgery, 2015, 40, 2017-2025.	0.7	15
224	A novel rat model of hip pain by intra-articular injection of nerve growth factor-characteristics of sensory innervation and inflammatory arthritis. Modern Rheumatology, 2015, 25, 931-936.	0.9	12
225	Pain from intra-articular NGF or joint injury in the rat requires contributions from peptidergic joint afferents. Neuroscience Letters, 2015, 604, 193-198.	1.0	24
226	Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (Part 2). Osteoarthritis and Cartilage, 2015, 23, S43-S58.	0.6	12
227	Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis). Reproductive Toxicology, 2015, 53, 105-118.	1.3	15
228	A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis and Cartilage, 2015, 23, S8-S17.	0.6	135
229	Imaging atlas for eligibility and on-study safety of potential shoulder adverse events in anti-NGF studies (Part 3). Osteoarthritis and Cartilage, 2015, 23, S59-S68.	0.6	6

#	Article	IF	Citations
230	Imaging atlas for eligibility and on-study safety of potential knee adverse events in anti-NGF studies (Part 1). Osteoarthritis and Cartilage, 2015, 23, S22-S42.	0.6	29
231	Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis and Cartilage, 2015, 23, S18-S21.	0.6	136
233	A random, caseâ€control study on the efficacy and safety of <scp>W</scp>eishi <scp>B</scp>itong <scp>X</scp>ifang fumigation for mild and moderate knee osteoarthritis patients. International Journal of Rheumatic Diseases, 2015, 18, 502-507.	0.9	11
234	Pathomechanisms of discogenic low back pain in humans and animal models. Spine Journal, 2015, 15, 1347-1355.	0.6	123
235	Management of Osteoarthritis with Avocado/Soybean Unsaponifiables. Cartilage, 2015, 6, 30-44.	1.4	65
236	Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Annals of the Rheumatic Diseases, 2015, 74, 1202-1211.	0.5	118
237	Antagonistes du nerve growth factor (NGF)Â: des antalgiques dâ€™avenirÂ?. Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT /Overlo	0.0	2
238	Mechanical allodynia. Pflugers Archiv European Journal of Physiology, 2015, 467, 133-139.	1.3	98
239	Nerve Growth Factor Regulation by TNF-Î±and IL-1Î²in Synovial Macrophages and Fibroblasts in Osteoarthritic Mice. Journal of Immunology Research, 2016, 2016, 1-8.	0.9	54
240	Anti-nerve growth factor in pain management: current evidence. Journal of Pain Research, 2016, 9, 373.	0.8	111
241	The Genetics of Osteoarthritis: A Review. Journal of Functional Morphology and Kinesiology, 2016, 1, 140-153.	1.1	42
242	Editorial: Synovitis and Pain Sensitization. Arthritis and Rheumatology, 2016, 68, 561-562.	2.9	4
243	Editorial: Pain Relief in Osteoarthritis: The Potential for a Perfect Storm. Arthritis and Rheumatology, 2016, 68, 270-273.	2.9	8
244	Nociceptive Sensitizers Are Regulated in Damaged Joint Tissues, Including Articular Cartilage, When Osteoarthritic Mice Display Pain Behavior. Arthritis and Rheumatology, 2016, 68, 857-867.	2.9	73
245	Non-operative management of osteoarthritis of the knee joint. Journal of Clinical Orthopaedics and Trauma, 2016, 7, 170-176.	0.6	68
246	<scp>NGF</scp>/TrkA Signaling as a Therapeutic Target for Pain. Pain Practice, 2016, 16, 175-182.	0.9	92
247	PKCÎ´null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal outgrowth. Annals of the Rheumatic Diseases, 2016, 75, 2133-2141.	0.5	45
248	Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials. Pain Medicine, 2017, 18, pnw262.	0.9	50

#	Article	IF	Citations
249	Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. International Journal of Clinical Practice, 2016, 70, 493-505.	0.8	30
250	Adelmidrol, in combination with hyaluronic acid, displays increased anti-inflammatory and analgesic effects against monosodium iodoacetate-induced osteoarthritis in rats. Arthritis Research and Therapy, 2016, 18, 291.	1.6	55
251	Nociceptive phenotype alterations of dorsal root ganglia neurons innervating the subchondral bone in osteoarthritic rat knee joints. Osteoarthritis and Cartilage, 2016, 24, 1596-1603.	0.6	40
252	Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study. Clinical Therapeutics, 2016, 38, 1435-1450.	1.1	23
253	Effect of administration of antibodies against nerve growth factor in a rat model of muscle injury. Injury, 2016, 47, 609-612.	0.7	4
254	A Felineâ€Specific Antiâ€Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Diseaseâ€"Associated Pain: A Pilot Proof of Concept Study. Journal of Veterinary Internal Medicine, 2016, 30, 1138-1148.	0.6	51
255	In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Antiâ€Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats. Journal of Veterinary Internal Medicine, 2016, 30, 1129-1137.	0.6	21
256	Hypofunctional TrkA Accounts for the Absence of Pain Sensitization in the African Naked Mole-Rat. Cell Reports, 2016, 17, 748-758.	2.9	51
257	Skeletal complications in cancer patients with bone metastases. International Journal of Urology, 2016, 23, 825-832.	0.5	95
258	Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain. Journal of Bone and Mineral Research, 2016, 31, 911-924.	3.1	181
259	Monoclonal antibodies for the treatment of osteoarthritis. Expert Opinion on Biological Therapy, 2016, 16, 1529-1540.	1.4	24
260	Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nature Reviews Rheumatology, 2016, 12, 580-592.	3.5	917
261	Osteoarthritis: from pathogenic mechanisms and recent clinical developments to novel prospective therapeutic options. Drug Discovery Today, 2016, 21, 1932-1937.	3.2	74
262	The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. Journal of Medicinal Chemistry, 2016, 59, 10084-10099.	2.9	78
264	Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Research, 2016, 4, 15040.	5.4	355
265	Bone pain in knee osteoarthritis. Pain Research, 2016, 31, 197-202.	0.1	0
266	Nerve growth factor & TrkA as novel therapeutic targets in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 37-50.	3.3	39
267	The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis and Cartilage, 2016, 24, 1587-1595.	0.6	48

#	Article	IF	Citations
268	Anti-NGF monoclonal antibody muMab 911 does not deplete neurons in the superior cervical ganglia of young or old adult rats. Journal of Chemical Neuroanatomy, 2016, 76, 133-141.	1.0	5
269	Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis. Arthritis Research and Therapy, 2016, 18, 97.	1.6	47
270	The brainâ€“joint axis in osteoarthritis: nerves, circadian clocks and beyond. Nature Reviews Rheumatology, 2016, 12, 508-516.	3.5	53
271	New insights into perineural invasion of pancreatic cancer: More than pain. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 111-122.	3.3	39
272	Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain. British Journal of Clinical Pharmacology, 2016, 81, 688-699.	1.1	18
273	Fracture painâ€”Traveling unknown pathways. Bone, 2016, 85, 107-114.	1.4	34
274	Limited efficacy of COX-2 inhibitors on nerve growth factor and metalloproteinases expressions in human synovial fibroblasts. Journal of Orthopaedic Science, 2016, 21, 381-388.	0.5	13
275	New approaches to treating pain. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1103-1119.	1.0	35
276	Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis and Cartilage, 2016, 24, 776-785.	0.6	24
277	Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition. Expert Opinion on Therapeutic Patents, 2016, 26, 291-295.	2.4	2
278	Tanezumab Reduces Pain in Women with Interstitial Cystitis/Bladder Pain Syndrome and Patients with Nonurological Associated Somatic Syndromes. Journal of Urology, 2016, 195, 942-948.	0.2	37
279	Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis. Annals of the Rheumatic Diseases, 2016, 75, 1246-1254.	0.5	78
280	Neurotrophic factors and their inhibitors in chronic pain treatment. Neurobiology of Disease, 2017, 97, 127-138.	2.1	37
281	Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy. Clinical Journal of Pain, 2017, 33, 99-108.	0.8	13
282	Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Research, 2017, 5, 16044.	5.4	731
283	Anti-NGF treatments for pain â€" two steps forward, one step back?. Nature Reviews Rheumatology, 2017, 13, 76-78.	3.5	44
284	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 â€“ Part II. Expert Opinion on Therapeutic Patents, 2017, 27, 831-849.	2.4	41
285	What's pain (sensitization) got to do with it? Microgliosis may be a treatment target in osteoarthritis-related pain sensitization. Osteoarthritis and Cartilage, 2017, 25, 613-615.	0.6	2

#	Article	IF	Citations
286	Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. Annals of the Rheumatic Diseases, 2017, 76, 295-302.	0.5	40
287	Antiâ€“nerve growth factor therapy increases spontaneous day/night activity in mice with orthopedic surgeryâ€“induced pain. Pain, 2017, 158, 605-617.	2.0	12
288	NGF-TrkA signaling in sensory nerves is required for skeletal adaptation to mechanical loads in mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3632-E3641.	3.3	124
289	Design, synthesis and SAR of substituted indoles as selective TrkA inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2695-2701.	1.0	4
290	Nerve Growth Factor and Pain Mechanisms. Annual Review of Neuroscience, 2017, 40, 307-325.	5.0	179
291	Pain sensation in human osteoarthritic knee joints is strongly enhanced by diabetes mellitus. Pain, 2017, 158, 1743-1753.	2.0	58
292	Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment. Seminars in Arthritis and Rheumatism, 2017, 47, 323-330.	1.6	12
293	Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?. Current Opinion in Rheumatology, 2017, 29, 110-118.	2.0	53
294	Hopes for the Future of Pain Control. Pain and Therapy, 2017, 6, 117-128.	1.5	42
295	Mechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain. Molecular Pain, 2017, 13, 174480691769701.	1.0	59
296	Structural characterization of nonactive site, TrkA-selective kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E297-E306.	3.3	39
297	Biologic drugs as analgesics for the management of osteoarthritis. Seminars in Arthritis and Rheumatism, 2017, 46, 687-691.	1.6	19
298	Tanezumab in the treatment of chronic musculoskeletal conditions. Expert Opinion on Biological Therapy, 2017, 17, 245-254.	1.4	25
299	Measuring and realizing the translational significance of preclinical inÂvivo studies of painful osteoarthritis. Osteoarthritis and Cartilage, 2017, 25, 376-384.	0.6	9
300	Monoclonal antibodies for chronic pain: A practical review of mechanisms and clinical applications. Molecular Pain, 2017, 13, 174480691774023.	1.0	21
301	Nerve growth factor regulation and production by macrophages in osteoarthritic synovium. Clinical and Experimental Immunology, 2017, 190, 235-243.	1.1	58
302	Transforming growth factor activating kinase 1 regulates extracellular matrix degrading enzymes and pain-related molecule expression following tumor necrosis factor-Î± stimulation of synovial cells: an in vitro study. BMC Musculoskeletal Disorders, 2017, 18, 283.	0.8	22
303	The effect of instruction in analgesic use compared with neuromuscular exercise on knee-joint load in patients with knee osteoarthritis: a randomized, single-blind, controlled trial. Osteoarthritis and Cartilage, 2017, 25, 470-480.	0.6	19

#	Article	IF	Citations
304	Longâ€Term Safety and Efficacy of Fulranumab in Patients With Moderateâ€toâ€Severe Osteoarthritis Pain: A Phase II Randomized, Doubleâ€Blind, Placeboâ€Controlled Extension Study. Arthritis and Rheumatology, 2017, 69, 763-773.	2.9	30
305	Mechanism and therapeutic effectiveness of nerve growth factor in osteoarthritis pain. Therapeutics and Clinical Risk Management, 2017, Volume 13, 951-956.	0.9	23
306	A Novel Small Molecule GDNF Receptor RET Agonist, BT13, Promotes Neurite Growth from Sensory Neurons in Vitro and Attenuates Experimental Neuropathy in the Rat. Frontiers in Pharmacology, 2017, 8, 365.	1.6	45
307	Molecular Mechanisms That Contribute to Bone Marrow Pain. Frontiers in Neurology, 2017, 8, 458.	1.1	31
308	Mechanisms of Osteoarthritic Pain. Studies in Humans and Experimental Models. Frontiers in Molecular Neuroscience, 2017, 10, 349.	1.4	156
309	Link N as a therapeutic agent for discogenic pain. JOR Spine, 2018, 1, e1008.	1.5	5
310	Emerging Treatment Models in Rheumatology: Challenges for Osteoarthritis Trials. Arthritis and Rheumatology, 2018, 70, 1175-1181.	2.9	28
311	Implantation of hyaluronic acid hydrogel prevents the pain phenotype in a rat model of intervertebral disc injury. Science Advances, 2018, 4, eaaq0597.	4.7	90
312	What is new in pain modification in osteoarthritis?. Rheumatology, 2018, 57, iv99-iv107.	0.9	49
313	Spontaneous painful disease in companion animals can facilitate the development of chronic pain therapies for humans. Osteoarthritis and Cartilage, 2018, 26, 175-183.	0.6	41
314	Positive-Feedback Regulation of Subchondral H-Type Vessel Formation by Chondrocyte Promotes Osteoarthritis Development in Mice. Journal of Bone and Mineral Research, 2018, 33, 909-920.	3.1	60
315	Responsiveness of Single versus Composite Measures of Pain in Knee Osteoarthritis. Journal of Rheumatology, 2018, 45, 1308-1315.	1.0	11
316	Gait analysis and weight bearing in pre-clinical joint pain research. Journal of Neuroscience Methods, 2018, 300, 92-102.	1.3	27
317	The effect of intraâ€articular injection of autologous bone marrow stem cells on pain and knee function in patients with osteoarthritis. International Journal of Rheumatic Diseases, 2018, 21, 140-147.	0.9	65
318	Topical thermal therapy with hot packs suppresses physical inactivity-induced mechanical hyperalgesia and up-regulation of NGF. Journal of Physiological Sciences, 2018, 68, 629-637.	0.9	12
319	Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. Journal of International Medical Research, 2018, 46, 326-334.	0.4	49
320	Role of TrkA signalling and mast cells in the initiation of osteoarthritis pain in the monoiodoacetate model. Osteoarthritis and Cartilage, 2018, 26, 84-94.	0.6	45
321	Antiâ€“nerve growth factor does not change physical activity in normal young or aging mice but does increase activity in mice with skeletal pain. Pain, 2018, 159, 2285-2295.	2.0	9

#	Article	IF	Citations
322	Antiâ€“nerve growth factor therapy attenuates cutaneous hypersensitivity and musculoskeletal discomfort in mice with osteoporosis. Pain Reports, 2018, 3, e652.	1.4	5
325	Growth factor signalling in osteoarthritis. Growth Factors, 2018, 36, 187-195.	0.5	34
326	Novel treatments for osteoarthritis: a recent update. Open Access Rheumatology: Research and Reviews, 2018, Volume 10, 135-140.	0.8	27
327	Investigational drugs for the treatment of osteoarthritis, an update on recent developments. Expert Opinion on Investigational Drugs, 2018, 27, 881-900.	1.9	44
328	Systemic Depletion of Nerve Growth Factor Inhibits Disease Progression in a Genetically Engineered Model of Pancreatic Ductal Adenocarcinoma. Pancreas, 2018, 47, 856-863.	0.5	38
329	First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain. Pain Reports, 2018, 3, e653.	1.4	13
330	Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis. Journal of Pain Research, 2018, Volume 11, 151-164.	0.8	30
331	Mechanisms of Osteoarthritis (OA) Pain. Current Osteoporosis Reports, 2018, 16, 611-616.	1.5	166
332	IL4-10 fusion protein has chondroprotective, anti-inflammatory and potentially analgesic effects in the treatment of osteoarthritis. Osteoarthritis and Cartilage, 2018, 26, 1127-1135.	0.6	27
333	Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments. Toxicologic Pathology, 2018, 46, 408-420.	0.9	7
334	Japanese GWAS identifies variants for bust-size, dysmenorrhea, and menstrual fever that are eQTLs for relevant protein-coding or long non-coding RNAs. Scientific Reports, 2018, 8, 8502.	1.6	11
335	Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues. Journal of Toxicological Sciences, 2018, 43, 1-10.	0.7	15
336	Synovial nerve fiber density decreases with naturally-occurring osteoarthritis in horses. Osteoarthritis and Cartilage, 2018, 26, 1379-1388.	0.6	15
337	Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain. Journal of Medicinal Chemistry, 2018, 61, 6779-6800.	2.9	27
338	Tanezumab: a selective humanized mAb for chronic lower back pain. Therapeutics and Clinical Risk Management, 2018, Volume 14, 361-367.	0.9	10
339	Role of the Bone Microenvironment in the Development of Painful Complications of Skeletal Metastases. Cancers, 2018, 10, 141.	1.7	20
340	Effects of carrageenan induced synovitis on joint damage and pain in a rat model of knee osteoarthritis. Osteoarthritis and Cartilage, 2018, 26, 1369-1378.	0.6	23
341	New Insights in Understanding and Treating Bone Fracture Pain. Current Osteoporosis Reports, 2018, 16, 325-332.	1.5	55

#	Article	IF	Citations
342	Neurotrophic Factors. , 2018, , 55-64.		3
344	Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review. Cells, 2019, 8, 818.	1.8	101
345	Bioanalytical assays in support of tanezumab developmental and reproductive toxicity studies: challenges and learnings. Bioanalysis, 2019, 11, 1205-1214.	0.6	0
346	Problems with Developments of Breakthrough Analgesics: Recent History via Scientometric Analysis. Journal of Anesthesia History, 2019, 5, 49-57.	0.2	2
347	Emerging Trend in the Pharmacotherapy of Osteoarthritis. Frontiers in Endocrinology, 2019, 10, 431.	1.5	68
348	CGRP and Painful Pathologies Other than Headache. Handbook of Experimental Pharmacology, 2019, 255, 141-167.	0.9	11
349	Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial. Osteoarthritis and Cartilage, 2019, 27, 1590-1598.	0.6	26
350	Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. Osteoarthritis and Cartilage, 2019, 27, 1599-1607.	0.6	35
351	Role of NGFâ€TrkA signaling in calcification of articular chondrocytes. FASEB Journal, 2019, 33, 10231-10239.	0.2	23
352	Tanezumab for Painful Osteoarthritis. JAMA - Journal of the American Medical Association, 2019, 322, 30.	3.8	11
353	Urinary Biomarkers in Overactive Bladder: Revisiting the Evidence in 2019. European Urology Focus, 2019, 5, 329-336.	1.6	35
354	The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis. ACS Symposium Series, 2019, , 107-123.	0.5	1
355	Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine. ACS Symposium Series, 2019, , 125-154.	0.5	1
356	The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain. ACS Symposium Series, 2019, , 155-183.	0.5	0
357	Discovery and Development of Non-Covalent, Reversible Brutonâ€™s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853). ACS Symposium Series, 2019, , 239-266.	0.5	2
358	Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. ACS Symposium Series, 2019, , 267-296.	0.5	0
359	Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection. ACS Symposium Series, 2019, , 297-322.	0.5	2
366	Synovial Cytokines Significantly Correlate with Osteoarthritis-Related Knee Pain and Disability: Inflammatory Mediators of Potential Clinical Relevance. Journal of Clinical Medicine, 2019, 8, 1343.	1.0	84

#	Article	IF	Citations
367	Analgesia without opioids. Nature, 2019, 573, S4-S6.	13.7	3
368	Monosodium iodoacetate-induced monoarthritis develops differently in knee versus ankle joint in rats. Neurobiology of Pain (Cambridge, Mass), 2019, 6, 100036.	1.0	14
369	The Pharmacology of Pain Associated With the Monoiodoacetate Model of Osteoarthritis. Frontiers in Pharmacology, 2019, 10, 974.	1.6	46
370	Human osteocyte expression of Nerve Growth Factor: The effect of Pentosan Polysulphate Sodium (PPS) and implications for pain associated with knee osteoarthritis. PLoS ONE, 2019, 14, e0222602.	1.1	17
371	Synthetic Routes for Venetoclax at Different Stages of Development. ACS Symposium Series, 2019, , 1-25.	0.5	0
372	Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC. ACS Symposium Series, 2019, , 27-59.	0.5	3
373	From Discovery to Market Readiness: The Research and Development of the Î²-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib. ACS Symposium Series, 2019, , 61-83.	0.5	2
374	Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis. ACS Symposium Series, 2019, , 185-238.	0.5	0
375	Discovery and Development of the First Antibodyâ€“Antibiotic Conjugate Linker-Drug. ACS Symposium Series, 2019, , 85-105.	0.5	2
376	Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment. Scientific Reports, 2019, 9, 14189.	1.6	14
377	Associations of Symptomatic Knee Osteoarthritis With Histopathologic Features in Subchondral Bone. Arthritis and Rheumatology, 2019, 71, 916-924.	2.9	53
378	Arthritic Conditions Affecting the Temporomandibular Joint. , 2019, , 1919-1954.		0
379	The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Doubleâ€Blind, Placeboâ€Controlled, Randomized Clinical Trial. Arthritis and Rheumatology, 2019, 71, 1824-1834.	2.9	63
380	The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2320-2326.	1.0	11
381	Chondroprotective Factors in Osteoarthritis: a Joint Affair. Current Rheumatology Reports, 2019, 21, 41.	2.1	18
382	Angiopoietin-like 2 upregulation promotes human chondrocyte injury via NF-Î°B and p38/MAPK signaling pathway. Journal of Bone and Mineral Metabolism, 2019, 37, 976-986.	1.3	15
383	Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. Journal of Clinical Investigation, 2019, 129, 1076-1093.	3.9	239
384	Novel Approaches to Persistent Pain Therapy. Trends in Pharmacological Sciences, 2019, 40, 367-377.	4.0	8

#	Article	IF	Citations
385	Transforming growth factor-Î² stimulates nerve growth factor production in osteoarthritic synovium. BMC Musculoskeletal Disorders, 2019, 20, 204.	0.8	16
386	Naproxen impairs load-induced bone formation, reduces bone toughness, and diminishes woven bone formation following stress fracture in mice. Bone, 2019, 124, 22-32.	1.4	23
387	LncRNA CASC2 is up-regulated in osteoarthritis and participates in the regulation of IL-17 expression and chondrocyte proliferation and apoptosis. Bioscience Reports, 2019, 39, .	1.1	31
388	Modulation of TARP Î³8â€“Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 345-363.	1.3	15
389	Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 676-682.	0.5	86
390	Chondrocyte dedifferentiation and osteoarthritis (OA). Biochemical Pharmacology, 2019, 165, 49-65.	2.0	264
391	Pain and immunity: implications for host defence. Nature Reviews Immunology, 2019, 19, 433-447.	10.6	271
392	Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 672-675.	0.5	37
393	Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip . Journal of Pain Research, 2019, Volume 12, 975-995.	0.8	40
394	Potential biomarkers for persistent and neuropathic pain therapy. , 2019, 199, 16-29.		28
395	Developing Modern Pain Therapies. Frontiers in Neuroscience, 2019, 13, 1370.	1.4	20
396	The NGF^{R100W}Mutation Specifically Impairs Nociception without Affecting Cognitive Performance in a Mouse Model of Hereditary Sensory and Autonomic Neuropathy Type V. Journal of Neuroscience, 2019, 39, 9702-9715.	1.7	18
397	Nerve growth factor continuously elevates in a rat rotator cuff tear model. Journal of Shoulder and Elbow Surgery, 2019, 28, 143-148.	1.2	10
398	NGF increases FGF2 expression and promotes endothelial cell migration and tube formation through PI3K/Akt and ERK/MAPK pathways in human chondrocytes. Osteoarthritis and Cartilage, 2019, 27, 526-534.	0.6	39
399	Nociceptive Physiology. , 2019, , 311-331.		0
401	Noninvasive Mechanical Joint Loading as an Alternative Model for Osteoarthritic Pain. Arthritis and Rheumatology, 2019, 71, 1078-1088.	2.9	14
402	Follistatinâ€like protein 1 (FSTL1) promotes chondrocyte expression of matrix metalloproteinase and inflammatory factors via the NFâ€ÎºB pathway. Journal of Cellular and Molecular Medicine, 2019, 23, 2230-2237.	1.6	20
403	Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Journal of Pain, 2019, 20, 440-452.	0.7	6

#	Article	IF	Citations
404	Mechanisms that drive bone pain across the lifespan. British Journal of Clinical Pharmacology, 2019, 85, 1103-1113.	1.1	45
405	Antiâ€nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. Veterinary Record, 2019, 184, 23-23.	0.2	61
407	Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis. Pharmaceutical Statistics, 2019, 18, 39-53.	0.7	3
408	Quantitative Systems Pharmacology and Empirical Models: Friends or Foes?. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 135-137.	1.3	8
409	Targeting nerve growth factor to relieve pain from osteoarthritis: What can we expect?. Joint Bone Spine, 2019, 86, 127-128.	0.8	10
410	Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 247-265.	2.9	44
411	Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic. Pharmacological Research, 2020, 154, 104240.	3.1	23
412	Neurotrophins, Cytokines, and Pain. , 0, , 770-816.		2
413	The COXâ€2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGFâ€î²1 and NGF expressions in chondrocytes. European Journal of Pain, 2020, 24, 209-222.	1.4	10
414	Vascular and nerve interactions. , 2020, , 205-218.		0
415	Gastrointestinal pain. Nature Reviews Disease Primers, 2020, 6, 1.	18.1	246
416	Peripheral brain-derived neurotrophic factor contributes to chronic osteoarthritis joint pain. Pain, 2020, 161, 61-73.	2.0	31
417	Supportive Care for the Cancer Patient. , 2020, , 286-329.		1
418	Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents. Journal of Controlled Release, 2020, 328, 985-999.	4.8	33
419	TrkA inhibitor promotes motor functional regeneration of recurrent laryngeal nerve by suppression of sensory nerve regeneration. Scientific Reports, 2020, 10, 16892.	1.6	6
420	Clinically Relevant Molecular Biomarkers for Use in Human Knee Osteoarthritis: A Systematic Review. Cartilage, 2021, 13, 1511S-1531S.	1.4	10
421	Emerging pharmaceutical therapies for osteoarthritis. Nature Reviews Rheumatology, 2020, 16, 673-688.	3.5	211
422	William D. Willis, Jr, MD, PhD Memorial Lecture: The evolutionary history of nerve growth factor and nociception. Pain, 2020, 161, S36-S47.	2.0	5

#	Article	IF	Citations
424	Nociceptive mechanisms driving pain in a post-traumatic osteoarthritis mouse model. Scientific Reports, 2020, 10, 15271.	1.6	14
425	Peripheral pain mechanisms in osteoarthritis. Pain, 2020, 161, S138-S146.	2.0	72
426	Evaluation of the Therapeutic Effect of Traditional Chinese Medicine on Osteoarthritis: A Systematic Review and Meta-Analysis. Pain Research and Management, 2020, 2020, 1-23.	0.7	14
427	Bone Angiogenesis and Vascular Niche Remodeling in Stress, Aging, and Diseases. Frontiers in Cell and Developmental Biology, 2020, 8, 602269.	1.8	31
428	A novel immunocompetent model of metastatic prostate cancerâ€induced bone pain. Prostate, 2020, 80, 782-794.	1.2	6
429	TRK inhibitors: managing on-target toxicities. Annals of Oncology, 2020, 31, 1109-1111.	0.6	1
430	Does Pain at an Earlier Stage of Chondropathy Protect Female Mice Against Structural Progression After Surgically Induced Osteoarthritis?. Arthritis and Rheumatology, 2020, 72, 2083-2093.	2.9	22
431	The Efficacy of Nerve Growth Factor Antibody for the Treatment of Osteoarthritis Pain and Chronic Low-Back Pain: A Meta-Analysis. Frontiers in Pharmacology, 2020, 11, 817.	1.6	17
432	Mechanism of aspirin-induced inhibition on the secondary hyperalgesia in osteoarthritis model rats. Heliyon, 2020, 6, e03963.	1.4	11
433	Pharmacotherapy for knee osteoarthritis: current and emerging therapies. Expert Opinion on Pharmacotherapy, 2020, 21, 797-809.	0.9	51
434	Placebo treatment with minimal adverse effects and low cost is ideal for management of osteoarthritis: A commentary on â€œThe efficacy and safety of extracorporeal shockwave therapy in knee osteoarthritis: A systematic review and meta-analysisâ€• International Journal of Surgery, 2020, 76, 3.	1.1	3
435	An understanding of bone pain: A narrative review. Bone, 2020, 134, 115272.	1.4	22
436	Understanding the Molecular Mechanisms Underlying the Pathogenesis of Arthritis Pain Using Animal Models. International Journal of Molecular Sciences, 2020, 21, 533.	1.8	33
437	Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study. Seminars in Arthritis and Rheumatism, 2020, 50, 387-393.	1.6	14
438	In vitro affinity optimization of an anti-BDNF monoclonal antibody translates to improved potency in targeting chronic pain states in vivo. MAbs, 2020, 12, 1755000.	2.6	7
439	Targeting neurotrophic factors: Novel approaches to musculoskeletal pain. , 2020, 211, 107553.		25
440	Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials. Clinical Rheumatology, 2021, 40, 2155-2165.	1.0	7
441	Nerve growth factor sensitizes nociceptors to Câ€fibre selective supraâ€threshold electrical stimuli in human skin. European Journal of Pain, 2021, 25, 385-397.	1.4	13

#	Article	IF	Citations
442	The evolution of nerve growth factor inhibition in clinical medicine. Nature Reviews Rheumatology, 2021, 17, 34-46.	3.5	71
443	Increased nerve growth factor expression in the synovial tissues of patients with rotator cuff tears. Molecular Pain, 2021, 17, 174480692110212.	1.0	3
444	The Effectiveness of Anti-Nerve Growth Factor Monoclonal Antibodies in the Management of Pain in Osteoarthritis of the Hip and Knee: A PRISMA Systematic Review and Meta-Analysis. Pain Medicine, 2021, 22, 1185-1204.	0.9	9
445	Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States. Arthritis Care and Research, 2022, 74, 1349-1358.	1.5	12
446	Diagnosis and Treatment of Hip and Knee Osteoarthritis. JAMA - Journal of the American Medical Association, 2021, 325, 568.	3.8	779
447	Management of Knee Osteoarthritis. Medical Clinics of North America, 2021, 105, 367-385.	1.1	12
448	Subchondral bone microenvironment in osteoarthritis and pain. Bone Research, 2021, 9, 20.	5.4	190
449	Parathyroid hormone attenuates osteoarthritis pain by remodeling subchondral bone in mice. ELife, 2021, 10, .	2.8	34
450	Local Administration of Low-Dose Nerve Growth Factor Antibody Reduced Pain in a Rat Osteoarthritis Model. International Journal of Molecular Sciences, 2021, 22, 2552.	1.8	2
451	ArthroseÂ: des traitements Ã venir aux traitements dâ€™avenir. Revue Du Rhumatisme Monographies, 2021, 88, 165-171.	0.0	0
452	Estrogen Regulation of the Expression of Pain Factor NGF in Rat Chondrocytes. Journal of Pain Research, 2021, Volume 14, 931-940.	0.8	3
454	Association of chronic pain with structural alteration and central sensitization in Japanese patients with knee osteoarthritis. Pain Research, 2021, 36, 15-23.	0.1	0
455	Quantifying noxious-evoked baseline sensitivity in neonates to optimise analgesic trials. ELife, 2021, 10, .	2.8	15
456	General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, <scp>Placeboâ€Controlled</scp> Trials. Arthritis Care and Research, 2022, 74, 918-928.	1.5	5
457	Targeting Nerve Growth Factor for Pain Management in Osteoarthritisâ€”Clinical Efficacy and Safety. Rheumatic Disease Clinics of North America, 2021, 47, 181-195.	0.8	13
458	Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study. Frontiers in Veterinary Science, 2021, 8, 610028.	0.9	20
459	Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?. European Journal of Pain, 2021, 25, 1525-1539.	1.4	9
460	Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration. Frontiers in Veterinary Science, 2021, 8, 687448.	0.9	3

#	Article	IF	Citations
461	Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 614753.	1.6	3
462	Immunological Events, Emerging Pharmaceutical Treatments and Therapeutic Potential of Balneotherapy on Osteoarthritis. Frontiers in Pharmacology, 2021, 12, 681871.	1.6	15
463	The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain. Journal of Pain Research, 2021, Volume 14, 1959-1967.	0.8	14
464	Nerve Growth Factor-Targeted Molecular Theranostics Based on Molybdenum Disulfide Nanosheet-Coated Gold Nanorods (MoS₂-AuNR) for Osteoarthritis Pain. ACS Nano, 2021, 15, 11711-11723.	7.3	41
465	Common and discrete mechanisms underlying chronic pain and itch: peripheral and central sensitization. Pflugers Archiv European Journal of Physiology, 2021, 473, 1603-1615.	1.3	24
466	Stimuliâ€Sensitive Nanotherapies for the Treatment of Osteoarthritis. Macromolecular Bioscience, 2021, 21, e2100280.	2.1	27
467	Expression of Substance P and Nerve Growth Factor in Degenerative Long Head of Biceps Tendon in Patients with Painful Rotator Cuff Tear. Journal of Pain Research, 2021, Volume 14, 2481-2490.	0.8	1
468	Association of Diabetic Peripheral Neuropathy with Vitamin D Levels Depends on Vitamin D Status. Medical Science Monitor, 2021, 27, e931244.	0.5	3
469	A novel mice model of acute flares in osteoarthritis elicited by intra-articular injection of cultured mast cells. Journal of Experimental Orthopaedics, 2021, 8, 75.	0.8	5
471	TrkA specific signalling pathways are critical for mechanical allodynia development and bone alterations in a mouse model of rheumatoid arthritis. Pain, 2021, Publish Ahead of Print, .	2.0	2
472	Monoclonal Antibodies for Chronic Pain Treatment: Present and Future. International Journal of Molecular Sciences, 2021, 22, 10325.	1.8	16
473	Osteoarthritis: From upcoming treatments to treatments yet to come. Joint Bone Spine, 2021, 88, 105206.	0.8	18
474	Biomarkers in Articular Cartilage Injury and Osteoarthritis. , 2021, , 11-23.		0
475	Ultra-purified alginate gel implantation decreases inflammatory cytokine levels, prevents intervertebral disc degeneration, and reduces acute pain after discectomy. Scientific Reports, 2021, 11, 638.	1.6	18
476	The Future of Pain Pharmacotherapy. , 2013, , 199-209.		1
477	Arthritic Conditions Affecting the Temporomandibular Joint. , 2017, , 1-36.		4
478	Neurophysiology and Itch Pathways. Handbook of Experimental Pharmacology, 2015, 226, 39-55.	0.9	18
479	Gene Expression in Skin, Muscle, and Dorsal Root Ganglion after Plantar Incision in the Rat. Anesthesiology, 2012, 117, 161-172.	1.3	49

#	Article	IF	Citations
480	Visual Sensorial Impairments in Neurodevelopmental Disorders: Evidence for a Retinal Phenotype in Fragile X Syndrome. PLoS ONE, 2014, 9, e105996.	1.1	35
481	Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis. PLoS ONE, 2016, 11, e0157105.	1.1	36
482	Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs. Aging, 2021, 13, 1051-1070.	1.4	6
483	Biological Therapies in Osteoarthritis. Current Pharmaceutical Design, 2015, 21, 2206-2215.	0.9	14
484	Partners in Crime: NGF and BDNF in Visceral Dysfunction. Current Neuropharmacology, 2019, 17, 1021-1038.	1.4	29
485	Resiniferatoxin for Pain Treatment: An Interventional Approach to Personalized Pain Medicine. Open Pain Journal, 2013, 6, 95-107.	0.4	54
486	Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis. Journal of Anaesthesiology Clinical Pharmacology, 2018, 34, 111.	0.2	32
487	Current understanding of the neuropathophysiology of pain in chronic pancreatitis. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 193.	0.5	13
488	Sensory impairment in mental retardation: a potential role for NGF. Archives Italiennes De Biologie, 2011, 149, 193-203.	0.1	16
489	Expression and Role of the TrkA Receptor in Pulmonary Inflammatory Diseases. , 0, , .		3
490	Aberrant subchondral osteoblastic metabolism modifies NaV1.8 for osteoarthritis. ELife, 2020, 9, .	2.8	34
491	Modern achievements in pharmacotherapy of osteoarthritis based on endo- and phenotyping. Farmakoekonomika, 2021, 14, 379-406.	0.4	2
492	Relative Efficacy and Safety of Tanezumab for Osteoarthritis. Clinical Journal of Pain, 2021, Publish Ahead of Print, 914-924.	0.8	6
493	Roles of mechanosensitive channel Piezo1/2 proteins in skeleton and other tissues. Bone Research, 2021, 9, 44.	5.4	63
494	NGF and pain. Drug Delivery System, 2011, 26, 457-460.	0.0	0
496	Statistical Properties of Two Ratio Measures Based on Pre- and Post Observed Values Which are Assumed as Bivariate Power Normal Distribution. Oyo Tokeigaku, 2012, 41, 53-68.	0.2	0
497	Osteoarthritis: genetic factors, animal models, mechanisms, and therapies. Frontiers in Bioscience - Elite, 2012, E4, 74.	0.9	35
498	Therapeutic Options in Osteoarthritis of the Hip or Knee. , 2014, , 27-35.		0

#	Article	IF	Citations
499	Osteoarthritis â€“ aetiology, assessment and management of a heterogeneous condition. Hamdan Medical Journal, 2014, 7, 167.	0.2	0
500	Neurotrophins and Pain. , 2014, , 1805-1823.		0
503	Arthritic Conditions Affecting the Temporomandibular Joint. , 2018, , 1-36.		0
504	PRIMARY OSTEOARTHRITIS OF THE KNEE: COMPARATIVE STUDY BETWEEN ARTHROSCOPIC DEBRIDEMENT AND SUPERVISED MEDICAL TREATMENT FOR THE STAGE (II AND III) OF THE DISEASE. Journal of Sulaimani Medical College, 2018, 8, 67-82.	0.0	0
508	Basic Research for Pain. , 2020, , 507-511.		0
509	An Update on Targets for Treating Osteoarthritis Pain: NGF and TRPV1. Current Treatment Options in Rheumatology, 2020, 6, 129-145.	0.6	8
510	Frunevetmab, a felinized <scp>antiâ€nerve growth factor</scp> monoclonal antibody, for the treatment of pain from osteoarthritis in cats. Journal of Veterinary Internal Medicine, 2021, 35, 2752-2762.	0.6	16
511	Design and conduct of confirmatory chronic pain clinical trials. Pain Reports, 2021, 6, e845.	1.4	11
513	Atypical Analgesics. , 2021, , .		0
514	Joint Pain. , 2020, , 571-591.		0
515	Aetiology of Hip Dysplasia: Genetic and Environmental Factors. , 2020, , 1-15.		0
516	The Osteochondral Unit. , 2022, , 83-93.		1
518	Managing pain in inflammatory bowel disease. Gastroenterology and Hepatology, 2011, 7, 592-601.	0.2	23
520	Developing antitussives the clinician's pipeline-what do we need?. Journal of Thoracic Disease, 2014, 6, S735-8.	0.6	2
521	Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clinical and Experimental Rheumatology, 2017, 35 Suppl 107, 85-87.	0.4	22
522	Tanezumab: Finally a Monoclonal Antibody for Pain Relief. Indian Journal of Palliative Care, 2018, 24, 384-385.	1.0	2
523	New Drug Treatments for Osteoarthritis: What is on the Horizon?. European Medical Journal Rheumatology, 2017, 2, 50-58.	0.0	20
524	Phenotypes of osteoarthritis: current state and future implications. Clinical and Experimental Rheumatology, 2019, 37 Suppl 120, 64-72.	0.4	26

#	Article	IF	Citations
525	Effectiveness of Various Dosages and Administration Methods of Tanezumab for the Treatment of Pain in Knee and Hip Osteoarthritis: a Network Meta-Analysis. Clinical Therapeutics, 2021, , .	1.1	1
526	Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review. BioDrugs, 2021, 35, 611-641.	2.2	13
527	Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions. Experimental and Molecular Medicine, 2021, 53, 1689-1696.	3.2	77
528	A harm reduction model to assess the impact of new treatments for pain over standard of care among patients with osteoarthritis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1652-1660.	0.5	2
529	THE NEUROPATHIC COMPONENT OF PAIN SYNDROME IN OSTEOARTHRITIS. Problemy ZdorovÊ¹Ã¢ I Ã¨kologii, 2018, , 8-11.	0.0	0
530	Understanding and managing pain in the arthritic synovial joint: an update. Companion Animal, 2022, 27, 1-5.	0.0	0
531	Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2110676.	1.2	4
532	MicroRNA-128-3p suppresses interleukin-1Î²-stimulated cartilage degradation and chondrocyte apoptosis via targeting zinc finger E-box binding homeobox 1 in osteoarthritis. Bioengineered, 2022, 13, 1736-1745.	1.4	6
533	Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain. British Journal of Clinical Pharmacology, 2022, 88, 3321-3334.	1.1	4
534	Efficacy and safety of biologic agents for the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210803.	1.2	8
537	Hierarchical functional nanoparticles boost osteoarthritis therapy by utilizing joint-resident mesenchymal stem cells. Journal of Nanobiotechnology, 2022, 20, 89.	4.2	16
539	Emerging and New Treatment Options for Knee Osteoarthritis. Current Rheumatology Reviews, 2022, 18, 20-32.	0.4	22
541	Neuropathic-like Pain in Fibrous Dysplasia/McCune-Albright Syndrome. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2258-e2266.	1.8	9
542	The Neuroimmune Interplay in Joint Pain: The Role of Macrophages. Frontiers in Immunology, 2022, 13, 812962.	2.2	9
544	Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis. Journal of the Neurological Sciences, 2022, 434, 120184.	0.3	4
545	Genome-wide association study of primary dysmenorrhea in the Taiwan Biobank validates associations near the NGF and IL1 gene loci. Journal of Human Genetics, 2022, , .	1.1	0
546	New Directions in the Development of Pharmacotherapy for Osteoarthrosis Based on Modern Concepts of the Disease Pathogenesis (A Review). Pharmaceutical Chemistry Journal, 2022, 55, 1282-1287.	0.3	0
547	Management of Knee Osteoarthritis. Rheumatic Disease Clinics of North America, 2022, 48, 549-567.	0.8	3

#	Article	IF	Citations
551	Silencing of circ_0000205 mitigates interleukin-1Î²-induced apoptosis and extracellular matrix degradation in chondrocytes via targeting miR-766-3p/ADAMTS5 axis. Innate Immunity, 2022, 28, 79-90.	1.1	6
552	Efficacy and Safety of Antiâ€“Nerve Growth Factor Antibody Therapy for Hip and Knee Osteoarthritis: A Meta-analysis. Orthopaedic Journal of Sports Medicine, 2022, 10, 232596712210885.	0.8	2
553	Osteoarthritis Pain. International Journal of Molecular Sciences, 2022, 23, 4642.	1.8	43
554	At the Crux of Joint Crosstalk: TGFÎ² Signaling in the Synovial Joint. Current Rheumatology Reports, 2022, 24, 184-197.	2.1	1
555	Neurogenic inflammation as a novel treatment target for chronic pain syndromes. Experimental Neurology, 2022, 356, 114108.	2.0	14
556	The challenges of treating osteoarthritis pain and opportunities for novel peripherally directed therapeutic strategies. Neuropharmacology, 2022, 213, 109075.	2.0	9
558	Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis. Biologics: Targets and Therapy, 0, Volume 16, 47-55.	3.0	2
559	Mechanisms of bone pain: Progress in research from bench to bedside. Bone Research, 2022, 10, .	5.4	15
560	Assessment of joint pharmacokinetics and consequences for the intraarticular delivery of biologics. Journal of Controlled Release, 2022, 348, 745-759.	4.8	7
561	Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials. EFORT Open Reviews, 2022, 7, 470-480.	1.8	1
562	Peripheral nerves in the tibial subchondral bone. Bone and Joint Research, 2022, 11, 439-452.	1.3	4
563	Involvement of nerve growth factor (NGF) in chronic neuropathic painÂâ€“ a systematic review. Reviews in the Neurosciences, 2023, 34, 75-84.	1.4	5
564	Is topical therapy a way forward in osteoarthritis?. International Journal of Rheumatic Diseases, 2022, 25, 723-724.	0.9	0
565	Senolytic drugs relieve pain by reducing peripheral nociceptive signaling without modifying joint tissue damage in spontaneous osteoarthritis. Aging, 2022, 14, 6006-6027.	1.4	9
567	Interplay between cellular changes in the knee joint, circulating lipids and pain behaviours in a slowly progressing murine model of osteoarthritis. European Journal of Pain, 2022, 26, 2213-2226.	1.4	4
568	The beneficial role of companion animals in translational pain research. Frontiers in Pain Research, 0, 3, .	0.9	3
569	Meteorin Alleviates Paclitaxel-Induced Peripheral Neuropathic Pain in Mice. Journal of Pain, 2023, 24, 555-567.	0.7	3
570	Biological Therapy for Osteoarthritis, Efficacy and Safety: Focus on Monoclonal Antibodies against Nerve Growth Factor and Fibroblast Growth Factor-18. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 697-704.	0.1	0

#	Article	IF	Citations
571	Recent advances in the pharmacotherapy of osteoarthritis. Research Results in Pharmacology, 2022, 8, 167-174.	0.1	0
573	Human TrkAR649W mutation impairs nociception, sweating and cognitive abilities: a mouse model of HSAN IV. Human Molecular Genetics, 2023, 32, 1380-1400.	1.4	1
574	Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain: A Meta-analysis of Randomized Controlled Trials. Clinical Neuropharmacology, 2023, 46, 6-16.	0.2	1
576	Intramuscular injection of nerve growth factor as a model of temporomandibular disorder: nature, time-course, and sex differences characterising the pain experience. Neurobiology of Pain (Cambridge,) Tj ETQq1 1 0.784314 rgBT /Over	0.7	0
577	Osteoarthritis today: Lost in translation?. Best Practice and Research in Clinical Rheumatology, 2022, 36, 101810.	1.4	7
578	New Drug Treatments for Osteoarthritis: What Is on the Horizon?. European Medical Journal (Chelmsford, England), 0, , 50-58.	3.0	3
579	Pharmacotherapy. , 2023, , 125-145.		0
580	Small molecule inhibitors of osteoarthritis: Current development and future perspective. Frontiers in Physiology, 0, 14, .	1.3	1